Results 221 to 230 of about 8,348,711 (246)

Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations. [PDF]

Front Pharmacol
Maletin N, Denda N, Paut Kusturica M, Rašković A, Babović S, Golušin Z.   +5 more
europepmc   +1 more source

Pathological Complete Response to Nab-Paclitaxel-Containing Neoadjuvant Regimens in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Salama RAA, El-Tanani M, Rabbani SA, Patni M, Bhongade B, Babiker R, Satyam SM, Rangraze IR, Wali AF, Talath S, Abdalla OE.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

What Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention?

Ca-A Cancer Journal for Clinicians, 1999
T Byers, Tim Byers
exaly  

Referral of Patients With Cancer for Participation in Randomized Clinical Trials: Ethical Considerations

Ca-A Cancer Journal for Clinicians, 1986
Robert J Levine
exaly  

Interventions With Family Caregivers of Cancer Patients: Meta-Analysis of Randomized Trials

Ca-A Cancer Journal for Clinicians, 2010
Lixin Song, Laurel L Northouse, Maria C. Katapodi   +2 more
exaly  

Sexual Response and Cancer

Ca-A Cancer Journal for Clinicians, 1987
Alex F Althausen
exaly